<DOC>
	<DOC>NCT02158624</DOC>
	<brief_summary>To establish the correlation between visual acuity improvement and QOL measurement after ranibizumab treatment for AMD patients.</brief_summary>
	<brief_title>Ranibizumab Treatment for Age-Related Macular Degeneretion</brief_title>
	<detailed_description />
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Active primary or recurrent subfoveal choroidal neovascularization lesion due to AMD Subjects of either gender age 50 years or older Visual acuity better than 0.05 decimal( 20/400 Snellen) Signed informed consent form Prior treatment for neovascular AMD in the study eye, for example, PDT or antiVEGF therapy Patients whose lesion site evaluated by FA examination is more than 12DA in subject eye Patients with treatment of triamcinolone intravitreal injection within 6 months in subject eye Patients with a history of intraocular surgical operation(including cataract)within 3 months in subject eye Patients with serious allergic history to such as fluorescein, indocyanine green, iodophors The pregnant or lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>